Ratings Henan Lingrui Pharmaceutical Co., Ltd.

Equities

600285

CNE000001501

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
24.85 ^CNY	-0.84%		-1.82%	+45.24%

May. 13	Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug	MT
Apr. 25	Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Strengths

Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
The average consensus view of analysts covering the stock has deteriorated over the past four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.24%	1.94B		-
DONG-E-E-JIAO CO.,LTD.	+42.38%	6.26B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.86%	4.49B		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+6.36%	3.29B		C
TASLY PHARMACEUTICAL GROUP CO., LTD	-11.28%	3.12B		B-
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.23%	2.5B	-	D+
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B	-	-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-0.98%	1.63B	-	-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-11.32%	1.56B		C-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+47.00%	1.52B		-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes